DaVita Statement on GLP-1 and Potential Implications on Chronic Kidney Disease
DaVita issued the following statement in response to news this week from Novo Nordisk, manufacturer of Ozempic®, a glucagon-like peptide 1 (GLP-1) receptor agonist indicated for type 2 diabetes,...
